Turnstone unveils $80M IPO

Today's Big News

Jul 21, 2023

J&J’s shrinking infectious disease and vaccine plans leave partners in limbo 


Passage decides 26% of staff, 2 execs not needed on voyage deeper into clinic


Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales


[Sponsored] Optimize Your Drug Development Timeline With This Dosage Form


Turnstone Biologics turns fortunes around with $80M IPO haul


Chutes & Ladders—Stanford president resigns after investigation 

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

J&J’s shrinking infectious disease and vaccine plans leave partners in limbo

Cidara Therapeutics has yet to hear whether Janssen is formally ending a collaboration on flu prophylaxis, saying it intends to trudge ahead with development until hearing otherwise. Janssen no longer lists the partnered asset in its pipeline.
11-14
Sep
Philadelphia, PA
 

Top Stories

Passage decides 26% of staff, 2 execs not needed on voyage deeper into clinic

In a tricky financial climate, we’re increasingly used to hearing about biotechs reducing head count for their early-stage R&D work. But Passage Bio has decided to go in the other direction, laying off employees in its chemistry, manufacturing and controls group to prioritize its development strategy.

Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales

Up to 500 roles at Idorsia are at risk as the Swiss biotech tries to halve its cash burn while it waits for its approved insomnia treatment Quviviq to pay off.

Optimize Your Drug Development Timeline With This Dosage Form

Optimize Your Drug Development Timeline With This Dosage Form Can you name five benefits of using liquid-filled, hard-shell capsules in drug development over other solid oral dosage forms? Find out!

Turnstone Biologics turns fortunes around with $80M IPO haul

Turnstone Biologics has brought in $80 million from its IPO in some welcome good news for a biotech looking to escape the shadow of abandoned Big Pharma partnerships.

Chutes & Ladders—Stanford president resigns after investigation

Marc Tessier-Lavigne has resigned from his post as president of Stanford University after months of sidestepping allegations that select research he oversaw was manipulated.

Integrated Biosciences' optogenetics platform illuminates aging pathways in cells

After shedding light on the cellular stress response, the researchers plan to pair their platform with artificial intelligence to identify druggable pathways, de-risking future clinical trials.

‘The Top Line’: The chemotherapy drug shortage, plus this week’s headlines

This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines

Pfizer's massive North Carolina plant heavily damaged by tornado, prompting new US drug supply fears

One of the world’s largest sterile injectables plants has landed in the path of a devastating act of nature. Wednesday, Pfizer said its manufacturing facility in Rocky Mount, North Carolina, suffered damage from a tornado. All of the company's employees are safe and accounted for.

Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare

Despite the widespread hype surrounding new and powerful obesity medicines, the drugs are still out of reach for many Americans who could benefit. A group of lawmakers is working to change that.

J&J professes 'voracious' appetite for medtech M&A following Abiomed megadeal

The miniature heart pump maker Abiomed—which J&J picked up last year for $16.6 billion—accounted for nearly a third of J&J's quarterly medtech gains.

Sanders' latest bill devotes billions to primary care, clinician training. Republicans, hospitals aren't on board

The influential Democrat's legislation is slated for committee markup next week, but is already being speared by Republicans for its price tag and hospitals for measures requiring site-neutral payments.

Fierce Pharma Asia—Eisai's subcutaneous Leqembi study; Astellas' IRA lawsuit; and GSK's Taiwan recall

Eisai showed off "promising" results from a modeling and bioavailability study of its subcutaneous Leqembi formulation. Astellas joined the growing list of drugmakers taking on the Inflation Reduction Act with legal action. GSK pulled two batches of its Nucala in Taiwan after glass particles were found in one vial. Plus more.
 
Fierce podcasts

Don't miss an episode

‘The Top Line’: The chemotherapy drug shortage, plus this week’s headlines

This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines
 

Resources

Whitepaper

Five ways to get the most from your lab and manufacturing facilities

Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives.
Webinar

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.
Whitepaper

Improving the Patient Experience Through Research-Driven Design

Learn more about the current challenges and issues that eClinical technology providers are facing.

Research

Develop a cost-effective cGMP chemical sourcing strategy

The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
eBook

Medical Affairs Metamorphosis

This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members.
eBook

6 Tools Trial Sponsors Need to Take Action Earlier in Enrollment

Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions.
Whitepaper

Enhance the cost-effectiveness of your GMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows.
 

Industry Events

 

Upcoming Fierce Events

11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA
5-6
Oct
San Diego, CA

View all events